Can diabetes mellitus modify the plasma concentrations of rifampicin in patients under treatment for tuberculosis?

World Health Organization, 2018 Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância das Doenças Transmissíveis, 2019, 364 Stott, 2018, Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis, J Antimicrob Chemother, 73, 2305, 10.1093/jac/dky152 Alsultan, 2014, Therapeutic drug monitoring in the treatment of tuberculosis: an update, Drugs, 74, 839, 10.1007/s40265-014-0222-8 Babalik, 2013, Plasma concentrations of isoniazid and rifampin are decreased in adult pulmonary tuberculosis patients with diabetes mellitus, Antimicrob Agents Chemother, 57, 5740, 10.1128/AAC.01345-13 Verbeeck, 2016, Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring, Eur J Clin Pharmacol, 72, 905, 10.1007/s00228-016-2083-4 Alfarisi, 2018, Effect of diabetes mellitus on the pharmacokinetics and pharmacodynamics of tuberculosis treatment, Antimicrob Agents Chemother, 62, e01383, 10.1128/AAC.01383-18 Sociedade Brasileira de Diabetes, 2017, 36 Prasanthi, 2015, Development and validation of RP-HPLC method for simultaneous estimation of rifampicin, isoniazid and pyrazinamide in human plasma, J Anal Chem, 70, 1015, 10.1134/S1061934815080146 Fahimi, 2016, Isoniazid, rifampicin and pyrazinamide plasma concentrations 2 and 6h post dose in patients with pulmonary tuberculosis, Int J Tuberc Lung Dis, 17, 1602, 10.5588/ijtld.13.0019 Prahl, 2014, Clinical significance of 2h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study, J Antimicrob Chemother, 69, 2841, 10.1093/jac/dku210 Requena-Méndez, 2012, Pharmacokinetics of rifampin in peruvian tuberculosis patients with and without comorbid diabetes or HIV, Antimicrob Agents Chemother, 56, 2357, 10.1128/AAC.06059-11 Ruslami, 2010, Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes, Antimicrob Agents Chemother, 54, 1068, 10.1128/AAC.00447-09 Yu, 2019, Impact of metformin on the risk and treatment outcomes of tuberculosis in diabetics: a systematic review, BMC Infect Dis, 19, 859, 10.1186/s12879-019-4548-4 van Ingen, 2011, Why do we use 600mg of rifampicin in tuberculosis treatment?, Clin Infect Dis, 52, e194, 10.1093/cid/cir184 Wang, 2009, Impact of type 2 diabetes on manifestations and treatment outcome of pulmonary tuberculosis, Epidemiol Infect, 137, 203, 10.1017/S0950268808000782 Restrepo, 2014, Impact of diabetes on the natural history of tuberculosis, Diabetes Res Clin Pract, 106, 191, 10.1016/j.diabres.2014.06.011